IASLC faculty members from Europe, Asia, and North America will discuss systemic therapies including chemotherapy, immunotherapy, and targeted therapy for advanced stage lung cancer during the COVID-19 global pandemic. The faculty will share their experience and advice on
- how COVID-19 impacts their patient population
- changes made in the management of current and newly diagnosed lung cancer patients due to pandemic, including starting and stopping treatment and monitoring
- testing for COVID-19
- outcomes of COVID-19 positive lung cancer patients.
Format: There will be two presentations followed by ample time for questions from the audience.